Nov 4 (Reuters) - German Drugmaker BioNTech 22Uay.de on Monday Lowered Its Guidance for Full-Year Revenue, Citing Covid-19 Uptake and Price Levels, Inventory Write-Downs and Pfizer Pfe.n Charges.

The Company Now Expects 2024 Revenue to Be at the Low End of the Guidance Range of 2.5 to 3.1 Billion Euros ($2.72 - $3.38 Billion).

BioNTech, Whose Covid-19 Vaccine in Partnership With Pfizer Was Widely Used During the Pandemic, Reported Third-Quarter Revenue of 1.24 Billion Euros Compared to 895.3 Million Euros Year Ago, Helped by Earlier Approvals for Its Variant-Adapted Covid-19 Vaccines.

In August, the Mainz-Based Company Said Some 90% of Its Total Research and Development Spending Was Going Towards Non-Covid Related Activities, Mainly Oncology and Mrna.

"We Remain Focused on Advancing Our Late-Stage Oncology Product Candidates Towards Potential Registration," Said BioNTech's CEO Ugur Sahin.

The Company Is Aiming for Its First Oncology Launch in 2026.

($1 = 0.9176 Euros)

(Reporting by Anastasiia Kozlova and Amir Orusov, Editing by Rachel More)

((Anastasiia.kozlova@Thomsonreuters.com; Amir.orusov@Thomsonreuters.com))